Remove Immune Response Remove Nurses Remove Trials Remove Vaccine
article thumbnail

Vaccines and various response rates

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial?

Vaccine 148
article thumbnail

Are We Getting Closer to a Herpes Vaccine?

The Pharma Data

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Keeping tabs on Covid-19: Iceni Diagnostics creates new virus detection device and the RDIF announce its vaccine is more than 95 per cent efficient

The Pharma Data

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. One dose of the Sputnik V vaccine will cost less than $10 for international markets.

Virus 52
article thumbnail

People Should Know That COVID Vaccine Might Spur Transient Sickness: CDC Experts

The Pharma Data

24, 2020 – At least thee new COVID-19 vaccine candidates are already in the pipeline, will a roll-out expected early in the new year. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. ” Another vaccine candidate. . TUESDAY, Nov. Meanwhile, U.S.

Vaccine 52
article thumbnail

Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

The Pharma Data

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

article thumbnail

Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

The Pharma Data

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

FDA 40
article thumbnail

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

The Pharma Data

million doses of the approved Pfizer and Moderna COVID-19 vaccines had been distributed across the United States by Monday morning, just 2.1 That’s far too slow a pace, said one official charged with spearheading the vaccination of Americans. million vaccination tally — compiled by the U.S. . THURSDAY, Dec.

Vaccine 52